No Data
No Data
Madrigal Pharmaceuticals Q1 Loss Narrows
Madrigal Pharmaceuticals | 10-Q: Quarterly report
Madrigal Pharmaceuticals GAAP EPS of -$3.32 Beats by $0.41, Revenue of $137.3M Beats by $23.11M
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Loss $-3.32 Per Share, Vs. FactSet Est of $-3.94
Madrigal Pharmaceuticals | 8-K: Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Madrigal Pharmaceuticals 1Q Research and Development Expense $44.2M >MDGL